Daiichi Sankyo seeks wider rifampicin indications in Japan
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has made a regulatory submission in Japan to extend the approval of Rifadin (rifampicin) to the treatment of non-tuberculous mycobacterial disease (NTMD).